APG-157 / Aveta Biomics - LARVOL DELTA

Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab (clinicaltrials.gov) - P1/2 | N=30 | Not yet recruiting | Sponsor: Aveta Biomics, Inc.

New P1/2 trial • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oligodendroglioma • Oncology • Solid Tumor

Safety and Efficacy of APG-157 in Head and Neck Cancer (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Aveta Biomics, Inc. | Trial completion date: Apr 2023 ➔ Jul 2024 | Trial primary completion date: Apr 2023 ➔ Jul 2024

Trial completion date • Trial primary completion date • Head and Neck Cancer • Oncology • Oral Cancer • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia (clinicaltrials.gov) - P2 | N=32 | Recruiting | Sponsor: Elizabeth J Franzmann | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Oral Cancer • Solid Tumor

A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia (clinicaltrials.gov) - P2 | N=32 | Not yet recruiting | Sponsor: Elizabeth J Franzmann

New P2 trial • Oncology • Oral Cancer • Solid Tumor

Treatment of Recurrent GBM With APG-157 Via Expanded Access (clinicaltrials.gov) - P=N/A | N=N/A | Available | Sponsor: Aveta Biomics, Inc.

New trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Enhanced tumor control with a combination of APG-157 and immune checkpoint inhibitors for head and neck cancer. (ASCO 2022) - "These study results indicate that APG-157 is able to modulate the immune system and fecal microbial species that could potentially lead to improved anti-tumor immunity and warrants further studies to define mechanism and the potential for human clinical trial."

Checkpoint inhibition • Head and Neck Cancer • Immune Modulation • Inflammation • Oncology • Solid Tumor • CD8

Cell-Free RNA as a Novel Biomarker for Response to Therapy in Head & Neck Cancer. (PubMed, Front Oncol) - "A platelet-related transcriptional signature could be detected in cancer patients but not in healthy individuals, indicating a platelet-centric pathway involved in the development of HNC. These results from a Phase 1 study are a proof of principle of the utility of cfRNAs as non-invasive circulating biomarkers for monitoring the efficacy of APG-157 in HNC."

Biomarker • Journal • Head and Neck Cancer • Inflammation • Oncology • Solid Tumor

Safety and Efficacy of APG-157 in Head and Neck Cancer (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Aveta Biomics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Head and Neck Cancer • Oncology • Oral Cancer • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • IL1B • TNFA

Safety and Efficacy of APG-157 in Head and Neck Cancer (clinicaltrials.gov) - P2 | N=24 | Not yet recruiting | Sponsor: Aveta Biomics, Inc.

New P2 trial • Head and Neck Cancer • Oncology • Oral Cancer • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • IL1B • TNFA